CDK7-IN-2 |
| Catalog No.GC63980 |
CDK7-IN-2 est un puissant inhibiteur de CDK7. CDK7 est impliqué À la fois dans le contrÔle temporel du cycle cellulaire et dans l'activité transcriptionnelle. CDK7 est impliquée dans le processus d'initiation de la transcription par phosphorylation de la sous-unité Rbpl de l'ARN polymérase II (RNAPII). CDK7 a le potentiel pour la recherche sur les maladies cancéreuses, en particulier les cancers agressifs et difficiles À traiter (extrait du brevet WO2019099298A1, composé 1).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2326428-19-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1)[1].
[1]. David Andrew Coates, et al. Compounds useful for inhibiting cdk7. Patent WO2019099298A1.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *